Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Pembrolizumab and Radiation Therapy in Operable Breast Cancer
NCT03366844Phase 2Active, not recruiting
- Sponsor
- Stephen Shiao
- Start
- Dec 2017
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in breast cancer, sponsored by Stephen Shiao. Primary endpoints: Number of Patients Who do Not Necessitate a Delay in Standard of Care Treatment After Receiving the Investigational Combination of Preoperative Pembrolizumab and Radiation at 8 weeks and Changes in Tumor Infiltrating Lymphocyte Score at 8 weeks. Started Dec 2017; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03366844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366844.